Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Urtica dioica cataplasm, Placebo, Vitamin D, Resting conditions.
- Who it may be relevant to
- Registry conditions: Osgood-Schlatter Disease. Basic parameters: 7 years — 15 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Safety and Efficacy of Urtica Dioica Cataplasm in the Management of Osgood-Schlatter Disease in Young Athletes: A Study Protocol for Randomized, Double-blind, Placebo Controlled Clinical Trial
Overview
The primary objective of this clinical trial is to evaluate the efficacy and safety of a topical Urtica dioica cataplasm in managing knee pain and functional limitations in athletic children diagnosed with Osgood-Schlatter Disease. Efficacy will be assessed through changes in knee pain using the Visual Analog Scale (VAS) and functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Three groups will be tested: * UDC Group: topical application of Urtica dioica cataplasm * Standard Care Group: oral vitamin D supplementation and physical rest * Placebo Group: topical application of a placebo cataplasm using Beta vulgaris subsp. cicla
Interventions
- Other Urtica dioica cataplasm
Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period. - Other Placebo
Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use. - Drug Vitamin D
Participants will receive oral vitamin D. - Behavioral Resting conditions
Reduction in physical activity based on orthopedic advice.
Primary outcome measures
- Pain intensity [Time frame: At each clinical visit during the intervention period (three times a week during 6 weeks).]
Secondary outcome measures (2)
- Functional knee status [Time frame: Assessments will be done at baseline and after 6 weeks.]
- Return to sport [Time frame: 6 weeks]
Eligibility criteria
Inclusion criteria
- Healthy male children between 7 and 15 years of age
- Active in regular sports practice (e.g., football)
- Clinically confirmed diagnosis of OSD
Exclusion criteria
- Known allergy to Urtica dioica
- Presence of dermatological conditions or lesions on the knees
- Recent use of anti-inflammatory medications
- History of immune or chronic inflammatory diseases
- Diagnosis of any other bone disorder
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07096037 · UDC-OSD-2025